CSL Ltd Annual Report 2020

5.3.2 Fair Value of awards granted, vested and lapsed equity in 2020 The table below details the fair value at the date of grant for all awards granted 8 , vested and lapsed in 2020. The values are shown in Australian Dollars. Table 5: Grant Fair Value 8 The grant date of PSUs granted to P Perreault and A Cuthbertson was 23 October 2019. Security Tranche Grant Date Vest/Lapse Date Fair Value at Grant A$ Option 1 1 Oct 2015 15 Aug 2019 13.51 Right 1 1 Oct 2015 15 Aug 2019 60.92 Right 2/3 1 Oct 2015 15 Aug 2019 83.12 Notional Share 1 1 Oct 2016 30 Sep 2019 107.25 PSU 2 1 Oct 2017 1 Sep 2019 129.01 PSU 1 1 Sep 2018 1 Sep 2019 223.06 PSU 1 1 Sep 2019 1 Sep 2020 232.89 PSU 2 1 Sep 2019 1 Sep 2021 230.50 PSU 3 1 Sep 2019 1 Sep 2022 228.14 PSU 4 1 Sep 2019 1 Sep 2023 225.80 Restricted Share Unit (RSU) 1 1 Sep 2019 1 Mar 2020 234.10 5.3.3 Summary of Executive KMP granted, vested and lapsed equity in 2020 The table below summarises the details of equity awards granted, vested and lapsed in US Dollars for each Executive KMP. For awards granted, the maximum number of securities that may vest is shown. For accounting purposes, the maximum value of each grant is the fair value of the equity granted multiplied by the number of equity instruments granted, or remaining each year. Ultimately, the maximum value of the equity awards will be equal to the number of securities granted multiplied by the CSL share price at the time of vesting. The minimum number of securities and the value of the equity awards is zero if the equity award is fully lapsed. For Dr McKenzie, the awards granted include the 2020 annual LTI grant, and the awards provided on commencement of employment. Dr McKenzie, an accomplished global leader with diverse biotechnology experience, brought significant experience and leadership capabilities to CSL that will continue to drive CSL’s sustainable growth. A sign-on award was made to compensate for the loss of Biogen (prior employer) equity-based incentives Dr McKenzie held at the time of cessation of his employment with Biogen. The awards were pro-rated and aligned to conditions of the awards at Biogen – performance hurdled awards were discounted and replaced with CSL performance hurdled awards, and time-based awards were matched with CSL time-based awards. The awards were provided in the form of PSUs and RSUs, with each PSU and RSU being a conditional right to receive a share in CSL (or a cash equivalent payment). The vesting schedule was adjusted to match the dates on which CSL awards vest following testing of performance conditions – vesting periods were extended beyond those of the relevant Biogen incentives. No price is payable by Dr McKenzie on the grant or vesting of Rights awarded as a sign-on award. Further details of how remuneration is determined is set out in section 9.2 and details on the terms of the awards can be found in section 3.2.5 for the PSU grants, and section 11.2 for RSU grants. CSL Limited Annual Report 2020 79